Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Tell us AngelaL - what price do you need to take your money

<< Previous

Bullboard Posts

Next >>

Comment by Amazighon Jul 30, 2021 10:37am

117 Views

Post# 33631840

RE:RE:RE:RE:Tell us AngelaL - what price do you need to take your money

AngelaL wrote: If your question is at what price level I would sell my position, the answer is at no price level. I do not sell a good company when it is undervalued. I tend to buy more and average down. There is no rational reason to sell an undervalued stock unless the investor is undercapitalized and needs cash.

I think, AngelaL, he wants to know, in your opinion, what CLAS will be worth in 6 months, one year, or two years

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week